Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA/glutamate ratios

Bumetanide has been reported to alter synaptic excitation–inhibition (E-I) balance by potentiating the action of γ-aminobutyric acid (GABA), thereby attenuating the severity of autism spectrum disorder (ASD) in animal models. However, clinical evidence of its efficacy in young patients with ASD is l...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lingli, Huang, Chu-Chung, Dai, Yuan, Luo, Qiang, Ji, Yiting, Wang, Kai, Deng, Shining, Yu, Juehua, Xu, Mingyu, Du, Xiujuan, Tang, Yun, Shen, Chun, Feng, Jianfeng, Sahakian, Barbara J, Lin, Ching-Po, Li, Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026137/
https://www.ncbi.nlm.nih.gov/pubmed/32066666
http://dx.doi.org/10.1038/s41398-020-0692-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026137/
https://www.ncbi.nlm.nih.gov/pubmed/32066666
http://dx.doi.org/10.1038/s41398-020-0692-2

Ejemplares similares